Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Open access
Pratz, Keith W., Jonas, Brian A., Pullarkat, Vinod, Recher, Christian, Schuh, Andre C., Thirman, Michael J., Garcia, Jacqueline S., DiNardo, Courtney D., Vorobyev, Vladimir, Fracchiolla, Nicola S., Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, Döhner, Hartmut · 2022 · Journal of Clinical Oncology

Abstract

PURPOSE: There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10–3 in the VIALE-A trial. METHODS: The patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10–3 or 0.1%) with an estimated analytic sensitivity of 0.0037%-0.0027%. CRc, duration of remission (DoR), event-free survival (EFS), and overall survival (OS) were assessed. A multivariate Cox regression analysis identified prognostic factors associated with OS. RESULTS: One hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10–3 was achieved by 67 of 164 (41%), and 97 of 164 (59%) had MRD ≥ 10–3. The median DoR, EFS, and OS were not reached in patients with CRc and MRD < 10–3, and the 12-month estimates for DoR, EFS, and OS in this group were 81.2%, 83.2%, and 94.0%. Among patients with CRc and MRD ≥ 10–3, the median DoR, EFS, and OS were 9.7, 10.6, and 18.7 months. Multivariate analysis showed that CRc with MRD < 10–3 was a strong predictor of OS (adjusted hazard ratio = 0.285; 95% CI, 0.159 to 0.510; P < .001). CONCLUSION: Patients who achieved CRc and MRD < 10–3 with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10–3.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.01546

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 16

  1. National Comprehensive Cancer Network, 2021, NCCN Guidelines for Patients with Acute Myeloid Leukemia, Version 3.2021
  2. 10.1182/blood-2005-09-3724 · DOI · Paper page
  3. 10.1002/cncr.21723 · DOI · Paper page
  4. 10.1053/j.seminoncol.2008.04.009 · DOI
  5. 10.1007/s00277-015-2364-5 · doi:10.1007/s00277-015-2364-5
  6. 10.1200/JCO.2012.45.9628 · DOI · Paper page
  7. 10.1200/JCO.2013.49.1753 · DOI · Paper page
  8. 10.1038/leu.2017.285 · DOI
  9. 10.1182/blood-2016-08-733196 · DOI · Paper page
  10. 10.1182/blood-2017-09-801498 · DOI · Paper page
  11. Thermo Fisher Scientific, Real-Time PCR
  12. 10.3390/jcm9061714 · doi:10.3390/jcm9061714
  13. 10.1200/JCO.2003.04.036 · DOI · Paper page
  14. US Department of Health and Human Services: National Cancer Institute, 2018, Common Terminology Criteria for Adverse Events (CTCAE) v4.03
  15. 10.1182/bloodadvances.2020003717 · DOI
  16. 10.1056/NEJMoa1716863 · DOI · Paper page

Cited by

See all 179

Metadata

Authors
Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., Yeh, S.-P., Jang, J. H., Ozcan, M., Yamamoto, K., Illes, A., Zhou, Y., Dail, M., Chyla, B., Potluri, J., & Döhner, H.
Venue
Journal of Clinical Oncology
Published
2022-03-10
Volume
40
Issue
8
Pages
855-865
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4200103238
Cited by
179
References
1
FWCI
16.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. https://app.cochat.ai/papers/10.1200/jco.21.01546
The paper
Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., Yeh, S.-P., Jang, J. H., Ozcan, M., Yamamoto, K., Illes, A., Zhou, Y., Dail, M., Chyla, B., Potluri, J., & Döhner, H. (2022). Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.